What question did this study set out to answer?

The study aims to clarify how SLC7A5 expression relates to aggressive traits in breast cancer and its link to lymphatic spread.

April 18, 2026

Slc7a5 protein expression in breast cancer samples, relationship with clinical and morphological parameters of the tumor and its regional metastasis

Puntos clave

The study aims to clarify how SLC7A5 expression relates to aggressive traits in breast cancer and its link to lymphatic spread.
Analyzed tumor samples from 358 breast cancer patients.
Assessed SLC7A5 expression using immunohistochemistry.
Correlated SLC7A5 levels with clinicopathological features and lymph node status.
Utilized χ² test, Kruskal-Wallis test, and univariate logistic regression for analysis.
SLC7A5 was expressed in 55.6% of samples, particularly in aggressive tumors.
Strong correlation found between SLC7A5 and poor features like high tumor grade and ER-negative status.
Expression was more frequent in metastatic cases compared to non-metastatic (51.8% vs. 31.8%).
Increased positivity correlated with higher odds of lymph node involvement (2.26-6.5 times).

Resumen

Objective. To define the role of SLC7A5 expression in establishing an aggressive phenotype in primary breast cancer, specifically its correlation with major clinicopathological characteristics and the capacity for early lymphatic spread. Material and methods. The study included tumor samples from 358 breast cancer patients. SLC7A5 expression was assessed by immunohistochemistry and correlated with tumor parameters (size, histological type, grade (G), molecular subtype, ER, PR, HER2 status, Ki-67 index) and axillary lymph node status. Analysis was performed using the χ² test, Kruskal-Wallis test, and univariate logistic regression. Results. SLC7A5 expression was detected in 55.6% of cases (intense staining in 26.5%) and was associated with aggressive features: pT2-3 (p=0.033), G3 (p=0.001), Ki-67≥30% (p<0.001), ER-negative (p=0.022), and PR-negative status (p=0.013). A subtype-specific pattern was observed: maximal frequency in HER2-positive non-luminal tumors (80%), minimal in luminal A (42.8%; p<0.001). Expression in ≥10% of cells was more frequent in the lymph node metastasis group (51.8% vs. 31.8% in pN0; p<0.001), and metastatic risk increased with expression intensity (p<0.001). In age groups 18-44 and 60-74 years, as well as in ER-positive and G1 tumors, SLC7A5 positivity increased the odds of lymph node involvement by 2.26-6.5 times. Conclusion. SLC7A5 expression serves as an integral marker of breast cancer aggressiveness, associated with unfavorable immunophenotypes and independently predictive of lymphogenous metastasis. Its assessment may improve risk stratification and help identify candidates for LAT1 inhibitor-targeted therapy.

Me gusta

Guardar

Cite This Study

Кометова et al. (Thu,) studied this question.

synapsesocial.com/papers/69e31f9e40886becb653edac https://doi.org/https://doi.org/10.17116/patol20268802114

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar